Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Cellular Oncology
Erschienen in: Cellular Oncology 1/2014

01.02.2014 | Review

Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications

verfasst von: Eugenia Yiannakopoulou

Erschienen in: Cellular Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Familial breast cancer accounts for 20–30 % of all breast cancer cases. Mutations in the BRCA1 and BRCA2 genes account for the majority of high risk families with both early onset breast cancer and ovarian cancer. Most of the families with less than six breast cancer cases and no ovarian cancer do not carry BRCA1 or BRCA2 mutations that can be detected using routine sequencing protocols. Here, we aimed to review the etiology of familial breast cancer in cases without BRCA1 and BRCA2 mutations.

Results

After excluding BRCA1 and BRCA2 mutations, factors proposed to contribute to familial breast cancer include: chance clustering of apparently sporadic cases, shared lifestyle, monogenic inheritance, i.e., dominant gene mutations associated with a high risk (TP53, PTEN, STK11), dominant gene mutations associated with a relatively low risk (ATM, BRIP1, RLB2), recessive gene mutations associated with horizontal inheritance patterns (sister-sister), and polygenic inheritance where susceptibility to familial breast cancer is thought to be conferred by a large number of low risk alleles.

Conclusions

Current evidence suggests that in the majority of cases with BRCA1 and BRCA2 negative familial breast cancer the etiology is due to interactions of intermediate or low risk alleles with environmental and lifestyle factors. Thus, a careful selection of patients submitted to genetic testing is needed. Clearly, further research is required to fully elucidate the etiology of non-BRCA familial breast cancer.
Literatur
1.
J.C. Carroll, C. Cremin, J. Allanson, S.M. Blaine, H. Dorman, C.A. Gibbons et al., Hereditary breast and ovarian cancers. Can. Fam. Physicians 54, 1691–1692 (2008)
2.
S.E. Filippini, A. Vega, Breast cancer genes: beyond BRCA1 and BRCA2. Front. Biosci. (Landmark Ed). 18, 1358–1372 (2013)PubMedCrossRef
3.
M.E. Robson, Treatment of hereditary breast cancer. Semin. Oncol. 34, 389–391 (2007)
4.
T. Ripperger, D. Gadzicki, A. Meindl, B. Schlegelberger, Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur. J. Hum. Genet. 17, 722–731 (2009)PubMedCrossRef
5.
A. Osorio, A. Barroso, B. Martínez, A. Cebrián, J.M. San Román, F. Lobo et al., Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br. J. Cancer 82, 1266–1270 (2000)PubMedCentralPubMedCrossRef
6.
R. Sabatier, J. Adélaïde, P. Finetti, A. Ferrari, L. Huiart, H. Sobol et al., BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer. Genes, Chromosomes Cancer 49, 1143–1151 (2010)PubMedCrossRef
7.
M.A. Didraga, E.H. van Beers, S.A. Joosse, K.I. Brandwijk, R.A. Oldenburg, L.F. Wessels et al., A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients. Breast Cancer Res. Treat. 130, 425–436 (2011)PubMedCrossRef
8.
9.
D. Ford, D.F. Easton, M. Stratton, S. Narod, D. Goldgar, P. Devilee et al., Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62, 676–689 (1998)PubMedCentralPubMedCrossRef
10.
K.E. Malone, J.R. Daling, J.D. Thompson, C.A. O’Brien, L.V. Francisco, E.A. Ostrander, BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279, 922–929 (1998)PubMedCrossRef
11.
K.L. Nathanson, B.L. Weber, “Other” breast cancer susceptibility genes: searching for more holy grail. Hum. Mol. Genet. 10, 715–720 (2001)PubMedCrossRef
12.
C. Turnbull, N. Rahman, Genetic predisposition to breast cancer: past, present, and future. Annu. Rev. Genomics Hum. Genet. 9, 321–345 (2008)PubMedCrossRef
13.
F.P. Li, J.F. Fraumeni Jr., Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med. 71, 747–752 (1969)PubMedCrossRef
14.
15.
R.A. Eeles, Germline mutations in the TP53 gene. Cancer Surv. 25, 101–124 (1995)PubMed
16.
E.I. Palmero, M.I. Achatz, P. Ashton-Prolla, M. Olivier, P. Hainaut, Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr. Opin. Oncol. 22, 64–69 (2010)PubMedCrossRef
17.
S. Tutluer, M.D. Tanriover, G.S. Guven, Cowden syndrome: a major indication for extensive cancer surveillance. Med. Oncol. 29, 1365–1368 (2012)PubMedCrossRef
18.
J.A. Hobert, C. Eng, PTEN hamartoma tumor syndrome: an overview. Genet. Med. 11, 687–694 (2009)PubMedCrossRef
19.
G.M. Blumenthal, P.A. Dennis, PTEN hamartoma tumor syndromes. Eur. J. Hum. Genet. 16, 1289–1300 (2008)PubMedCrossRef
20.
S. Gustafson, K.M. Zbuk, C. Scacheri, C. Eng, Cowden syndrome. Semin. Oncol. 34, 428–434 (2007)PubMedCrossRef
21.
R.M. Cisco, J.M. Ford, J.A. Norton, Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery. Cancer 113(7Suppl), 1850–1856 (2008)PubMedCrossRef
22.
K.F. Becker, M.J. Atkinson, U. Reich, I. Becker, H. Nekarda, J.R. Siewert et al., E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 54, 3845–3852 (1994)PubMed
23.
G. Keller, H. Vogelsang, I. Becker, J. Hutter, K. Ott, S. Candidus et al., Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am. J. Pathol. 155, 337–342 (1999)PubMedCrossRef
24.
R.C. Fitzgerald, R. Hardwick, D. Huntsman, F. Carneiro, P. Guilford, V. Blair et al., Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J. Med. Genet. 47, 436–444 (2010)PubMedCentralPubMedCrossRef
25.
C. Caldas, F. Carneiro, H.T. Lynch, J. Yokota, G.L. Wiesner, S.M. Powell et al., Familial gastric cancer: overview and guidelines for management. J. Med. Genet. 36, 873–880 (1999)PubMed
26.
27.
L.A. Boardman, S.N. Thibodeau, D.J. Schaid, N.M. Lindor, S.K. McDonnell, L.J. Burgart et al., Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann. Intern. Med. 128, 896–899 (1998)PubMedCrossRef
28.
S. Matsuoka, M. Huang, S.J. Elledge, Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282, 1893–1897 (1998)PubMedCrossRef
29.
M. Weischer, S.E. Bojesen, A. Tybjaerg-Hansen, C.K. Axelsson, B.G. Nordestgaard, Increased risk of breast cancer associated with CHEK2*1100delC. J. Clin. Oncol. 25, 57–63 (2007)PubMedCrossRef
30.
C. Cybulski, D. Wokołorczyk, T. Huzarski, T. Byrski, J. Gronwald, B. Górski et al., A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res. Treat. 102, 119–122 (2007)PubMedCrossRef
31.
A. Desrichard, Y. Bidet, N. Uhrhammer, Y.J. Bignon, CHEK2 contribution to hereditary breast cancer in non-BRCA families. Breast Cancer Res. 13, R119 (2011)PubMedCentralPubMedCrossRef
32.
S.A. Narod, Testing for CHEK2 in the cancer genetics clinic: ready for prime time? Clin. Genet. 78, 1–7 (2010)PubMedCrossRef
33.
M. Weischer, S.E. Bojesen, C. Ellervik, A. Tybjaerg-Hansen, B.G. Nordestgaard, CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J. Clin. Oncol. 26, 542–548 (2008)PubMedCrossRef
34.
35.
A. Mavrou, G.T. Tsangaris, E. Roma, A. Kolialexi, The ATM gene and ataxia telangiectasia. Anticancer Res. 28, 401–405 (2008)PubMed
36.
S. Angèle, J. Hall, The ATM gene and breast cancer: is it really a risk factor? Mutat. Res. 462, 167–178 (2000)PubMedCrossRef
37.
J. Hall, The Ataxia-telangiectasia mutated gene and breast cancer: gene expression profiles and sequence variants. Cancer Lett. 227, 105–114 (2005)PubMedCrossRef
38.
A. Renwick, D. Thompson, S. Seal, P. Kelly, T. Chagtai, M. Ahmed et al., ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet. 38, 873–875 (2006)PubMedCrossRef
39.
40.
K.M. Mahdi, M.R. Nassiri, K. Nasiri, Hereditary genes and SNPs associated with breast cancer. Asian Pac. J. Cancer Prev. 14, 3403–3409 (2013)PubMedCrossRef
41.
N. Rahman, R.H. Scott, Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum. Mol. Genet. 16, R60–R66 (2007)PubMedCrossRef
42.
N. Rahman, S. Seal, D. Thompson, P. Kelly, A. Renwick, A. Elliott et al., PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 39, 165–167 (2007)PubMedCentralPubMedCrossRef
43.
M.F. Lavin, ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene 26, 7749–7758 (2007)PubMedCrossRef
44.
J.H. Lee, T.T. Paull, ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 308, 351–354 (2005)
45.
H.M. Hsu, H.C. Wang, S.T. Chen, G.C. Hsu, C.Y. Shen, J.C. Yu, Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. Cancer Epidemiol. Biomarkers Prev. 16, 2024–2032 (2007)PubMedCrossRef
46.
N. Bogdanova, S. Feshchenko, P. Schürmann, R. Waltes, B. Wieland, P. Hillemanns et al., Nijmegen Breakage Syndrome mutations and risk of breast cancer. Int. J. Cancer 122, 802–806 (2008)PubMedCrossRef
47.
P. van der Groep, E. van der Wall, P.J. van Diest, Pathology of hereditary breast cancer. Cell Oncol. 34, 71–88 (2011)CrossRef
48.
M.J. Ligtenberg, R.P. Kuiper, T.L. Chan, M. Goossens, K.M. Hebeda, M. Voorendt et al., Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat. Genet. 41, 112–117 (2009)PubMedCrossRef
49.
A.K. Win, N.M. Lindor, I. Winship, K.M. Tucker, D.D. Buchanan, J.P. Young et al., Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J. Natl. Cancer Inst. 105, 274–279 (2013)PubMedCrossRef
50.
S. Shanley, C. Fung, J. Milliken, J. Leary, R. Barnetson, M. Schnitzler et al., Breast cancer immunohistochemistry can be useful in triage of some HNPCC families. Fam. Cancer 8, 251–255 (2009)PubMedCrossRef
51.
Y.M. Hendriks, A. Wagner, H. Morreau, F. Menko, A. Stormorken, F. Quehenberger et al., Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 127, 17–25 (2004)PubMedCrossRef
52.
S.A. Madanikia, A. Bergner, X. Ye, J.O. Blakeley, Increased risk of breast cancer in women with NF1. Am. J. Med. Genet. A 158A, 3056–3060 (2012)PubMedCentralPubMedCrossRef
53.
X. Wang, A.M. Levin, S.E. Smolinski, F.D. Vigneau, N.K. Levin, M.A. Tainsky, Breast cancer and other neoplasms in women with neurofibromatosis type 1: a retrospective review of cases in the Detroit metropolitan area. Am. J. Med. Genet. A 158A, 3061–3064 (2012)PubMedCentralPubMedCrossRef
54.
S. Sharif, A. Moran, S.M. Huson, R. Iddenden, A. Shenton, E. Howard et al., Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J. Med. Genet. 44, 481–484 (2007)PubMedCrossRef
55.
D. Easton, K.A. Pooley, A.M. Dunning, P.D. Pharoah, D. Thompson, D.G. Ballinger et al., Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087–1093 (2007)PubMedCentralPubMedCrossRef
56.
R. Gramling, T.L. Lash, K.J. Rothman, H.J. Cabral, R. Silliman, M. Roberts et al., Family history of later-onset breast cancer, breast healthy behavior and invasive breast cancer among postmenopausal women: a cohort study. Breast Cancer Res. 12, R82 (2010)PubMedCentralPubMedCrossRef
57.
C. Turnbull, S. Ahmed, J. Morrison, D. Pernet, A. Renwick, M. Maranian et al., Genome-wide association study identifies five new breast cancer susceptibility loci. Nat. Genet. 42, 504–507 (2010)PubMedCentralPubMedCrossRef
58.
S. Wacholder, P. Hartge, R. Prentice, M. Garcia-Closas, H.S. Feigelson, W.R. Diver et al., Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med. 362, 986–993 (2010)PubMedCentralPubMedCrossRef
59.
D.F. Conrad, D. Pinto, R. Redon, L. Feuk, O. Gokcumen, Y. Zhang et al., Origins and functional impact of copy number variation in the human genome. Nature 464, 704–712 (2010)PubMedCentralPubMedCrossRef
60.
P. Stankiewicz, J.R. Lupski, Structural variation in the human genome and its role in disease. Annu. Rev. Med. 61, 437–455 (2010)PubMedCrossRef
61.
A.C. Krepischi, M.I. Achatz, E.M. Santos, S.S. Costa, B.C. Lisboa, H. Brentani et al., Germline DNA copy number variation in familial and early-onset breast cancer. Breast Cancer Res. 14, R24 (2012)PubMedCentralPubMedCrossRef
62.
63.
A.P. Feinberg, R. Ohlsson, S. Henikoff, The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7, 21–33 (2006)PubMedCrossRef
64.
A. de Bustros, B.D. Nelkin, A. Silverman, G. Ehrlich, B. Poiesz, S.B. Baylin, The short arm of chromosome 11 is a “hot spot” for hypermethylation in human neoplasia. Proc. Natl. Acad. Sci. U. S. A. 85, 5693–5697 (1988)PubMedCentralPubMedCrossRef
65.
M.J. Kempers, R.P. Kuiper, C.W. Ockeloen, P.O. Chappuis, P. Hutter, N. Rahner et al., Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 12, 49–55 (2011)PubMedCentralPubMedCrossRef
66.
T. Hansmann, G. Pliushch, M. Leubner, P. Kroll, D. Endt, A. Gehrig et al., Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancerand early-onset sporadic breast cancer. Hum. Mol. Genet. 21, 4669–4679 (2012)PubMedCrossRef
67.
M.P. Hitchins, Inheritance of epigenetic aberrations (constitutional epimutations) in cancer susceptibility. Adv. Genet. 70, 201–243 (2010)PubMedCrossRef
68.
J.M. Flanagan, S. Cocciardi, N. Waddell, C.N. Johnstone, A. Marsh, S. Henderson et al., DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am. J. Hum. Genet. 86, 420–433 (2010)PubMedCentralPubMedCrossRef
69.
M. Esteller, M.F. Fraga, M. Guo, J. Garcia-Foncillas, I. Hedenfalk, A.K. Godwin et al., DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet. 10, 3001–3007 (2001)PubMedCrossRef
70.
N. Loman, A. Bladström, O. Johannsson, A. Borg, H. Olsson, Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res. 5, R175–R186 (2003)PubMedCentralPubMedCrossRef
71.
72.
T. Tapia, S.V. Smalley, P. Kohen, A. Muñoz, L.M. Solis, A. Corvalan et al., Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics 3, 157–163 (2008)PubMedCrossRef
73.
E. Honrado, A. Osorio, R.L. Milne, M.F. Paz, L. Melchor, A. Cascón et al., Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Mod. Pathol. 20, 1298–1306 (2007)PubMedCrossRef
74.
I. Hedenfalk, D. Duggan, Y. Chen, M. Radmacher, M. Bittner, R. Simon et al., Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344, 539–548 (2001)PubMedCrossRef
75.
A.M. Dworkin, A.D. Spearman, S.Y. Tseng, K. Sweet, A.E. Toland, Methylation not a frequent “second hit” in tumors with germline BRCA mutations. Fam. Cancer 8, 339–346 (2009)PubMedCrossRef
76.
K. Hemminki, B. Chen, Familial association of prostate cancer with other cancers in the Swedish Family-Cancer Database. Prostate 65, 188–194 (2005)PubMedCrossRef
77.
M.P. Zeegers, L.J. Schouten, R.A. Goldbohm, P.A. van den Brandt, A compendium of familial relative risks of cancer among first degree relatives: a population-based study. Int. J. Cancer 123, 1664–1673 (2008)PubMedCrossRef
78.
A. Valeri, G. Fournier, V. Morin, J.F. Morin, E. Drelon, P. Mangin et al., Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives. Int. J. Cancer 86, 883–887 (2000)PubMedCrossRef
79.
A. Kong, V. Steinthorsdottir, G. Masson, G. Thorleifsson, P. Sulem, S. Besenbacher et al., Parental origin of sequence variants associated with complex diseases. Nature 462, 868–874 (2009)PubMedCentralPubMedCrossRef
80.
M. Tuna, M. Smid, J.W. Martens, J.A. Foekens, Prognostic value of acquired uniparental disomy (aUPD) in primary breast cancer. Breast Cancer Res. Treat. 132, 189–196 (2012)PubMedCrossRef
81.
C. Ellberg, G. Jönsson, H. Olsson, Can a phenotype for recessive inheritance in breast cancer be defined? Fam. Cancer 9, 525–530 (2010)PubMedCrossRef
82.
U. Güth, D. Müller, D.J. Huang, E. Obermann, H. Müller, Strictly defined familial male breast cancer. Fam. Cancer 10, 73–77 (2011)PubMedCrossRef
83.
G. Bostean, C.M. Crespi, W.J. McCarthy, Associations among family history of cancer, cancer screening and lifestyle behaviors: a population-based study. Cancer Causes Control 24, 1491–1503 (2013)PubMedCrossRef
Metadaten
Titel
Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications
verfasst von
Eugenia Yiannakopoulou
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 1/2014
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-013-0158-0

Weitere Artikel der Ausgabe 1/2014

Cellular Oncology 1/2014 Zur Ausgabe

Review

Clinical application of circulating tumor cells in breast cancer

Original Paper

Loss of NF2/Merlin expression in advanced sporadic colorectal cancer

Original Paper

Thymidylate synthase expression and p21WAF1/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy

Original Paper

A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells

Original Paper

Genetic gains and losses in oral squamous cell carcinoma: impact on clinical management

Original Paper

High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Open Access 22.02.2024 | Pathologie | Originalien

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

21.02.2024 | Thrombozytopenie | CME

Knochenmarkhistologie bei Zytopenien
Beitrag zur hämatologischen Differenzialdiagnostik

Open Access 21.02.2024 | Fettleber | Originalien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien
Automatische Quantifizierung von Leberverfettung